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Background: The equine infectious anemia virus (EIAV) is a lentivirus of the Retrovirus family, which causes
persistent infection in horses often characterized by recurrent episodes of high fever. It has a similar morphology
and life cycle to the human immunodeficiency virus (HIV). Its transmembrane glycoprotein, gp45 (analogous to
gp41 in HIV), mediates membrane fusion during the infection. However, the post-fusion conformation of EIAV gp45
has not yet been determined. EIAV is the first member of the lentiviruses for which an effective vaccine has been
successfully developed. The attenuated vaccine strain, FDDV, has been produced from a pathogenic strain by a series
of passages in donkey dermal cells. We have previously reported that a V/I505T mutation in gp45, in combination with
other mutations in gp90, may potentially contribute to the success of the vaccine strain. To this end, we now report on
our structural and biochemical studies of the gp45 protein from both wide type and vaccine strain, providing a
valuable structural model for the advancement of the EIAV vaccine.
Results: We resolved crystal structures of the ecto-domain of gp45 from both the wild-type EIAV and the vaccine
strain FDDV. We found that the V/I505T mutation in gp45 was located in a highly conserved d position within the
heptad repeat, which protruded into a 3-fold symmetry axis within the six-helix bundle. Our crystal structure analyses
revealed a shift of a hydrophobic to hydrophilic interaction due to this specific mutation, and further biochemical and
virological studies confirmed that the mutation reduced the overall stability of the six-helix bundle in post-fusion
conformation. Moreover, we found that altering the temperatures drastically affected the viral infectivity.
Conclusions: Our high-resolution crystal structures of gp45 exhibited high conservation between the gp45/gp41
structures of lentiviruses. In addition, a hydrophobic to hydrophilic interaction change in the EIAV vaccine strain
was found to modulate the stability and thermal-sensitivity of the overall gp45 structure. Our observations suggest that
lowering the stability of the six-helix bundle (post-fusion), which may stabilizes the pre-fusion conformation, might be
one of the reasons of acquired dominance for FDDV in viral attenuation.
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Lentiviruses infect mammals and induce various diseases
characterized by persistent infection and progressively
degenerative pathology. For example, the equine infec-
tious anemia virus (EIAV) triggers EIA characterized by
anemia, thrombocytopenia, edema, and other degenera-
tive symptoms in horses; and the infection of human
immunodeficiency virus (HIV) causes acquired immune
deficiency syndrome (AIDS) [1-4]. For HIV infection,
major advances have been achieved that help infected
individuals to control the viral load, but the virus still
cannot be completely eliminated from circulation in
individuals [5]. Despite three decades of research and
concerted efforts to develop an effective vaccine, the
levels of protection seen in most HIV trials have been
insufficient, except in a recent Thai trial (RV-144), which
has presented encouraging prospects for mild immunity
in the field of HIV vaccine development [6,7].
Lentiviruses rely on two glycoproteins, gp120/gp90
and gp41/gp45, that mediate attachment to the host cell
membrane and viral entry [8-13]. In the case of HIV,
after sequential binding of gp120 to its receptor (CD4)
and its co-receptor (CCR5/CXCR4), the fusion peptides
buried within the gp120/gp41 trimers are exposed and
mediate membrane fusion between the virus and host
cell [14-17]. The glycoprotein gp45 in EIAV plays a simi-
lar role by forming a hetero-dimer with glycoprotein
gp90 on viral surfaces, mediating membrane fusion dur-
ing viral invasion. The gp45/gp41 is somewhat seques-
tered from the viral surface, making it difficult for
neutralizing antibodies to target [18,19]. However, its
high sequence conservation and low level of glycosyla-
tion make the glycoprotein a potential target for vaccine
development as a broad range of antibodies can be
assessed. In past years, several antibodies specific to
gp41, including the 2 F5, 4E10 and 10E8, have been
successfully identified and have been shown to neutralize
HIV [20-22]. Although their mechanism of action is
unknown, the broad anti-HIV activity of these anti-
bodies has led to extensive studies for the crystal
structures of these antibodies and gp41 [23-28]. Previ-
ous X-ray crystallographic studies have confirmed that
the thermostable sub-domain of HIV gp41 folds into a
α-helical six-helix bundle, in which three NHR helices
form an interior, parallel coiled-coil trimer while three
CHR helices pack in an oblique, anti-parallel manner
into the highly conserved deep hydrophobic grooves
on the surface of the N-helical trimer [25,27,29]. The
crystal structure of HIV gp41, reported by Buzon, V
et al. (PDB code 2X7R), containing an FPPR (fusion
peptide proximal) and MPER (membrane proximal
external) region is the most complete structure to date
[30]. However, the structure of EIAV gp45, which has
a low sequence identity (approximately 20–25% accordingto BLAST) with HIV/SIV gp41, has not yet been
determined.
Several achievements have been accomplished in vac-
cine development against virus-induced diseases [4,31,32].
Examples of lentivirus vaccines include, the equine infec-
tious anemia virus (EIAV) and feline immunodeficiency
virus (FIV) [33]. The effective EIAV vaccine was initially
developed by both Chinese [34] and American scientists
[35]. In our previous studies, we have found the Val/Ile505
to Thr (V/I505T) mutation in gp45 to be highly associated
with the vaccine strains [36] and negatively correlated
with the severity of pathogenic symptom in horses [37]. In
the present study, we determined the crystal structure of
both the wild-type (WT) and V/I505T mutant of gp45.
The V/I505T mutation is located in the d position of the
heptad repeat, protruding toward the central axis within
the six-helix bundle, where high levels of conservation are
observed for a range of lentiviruses including HIV and
SIV. Along with biochemical and virological data, we
discuss the potential association and involvement of
this mutation within the vaccine strain.
Results
The crystal structure of EIAV gp45
In order to study the crystal structure of EIAV gp45, we
cloned the NHR and CHR regions of gp45 (strain LN40)
(Figure 1A) and connected them using a five residue
linker (GGSGG) [27]. The boundary of the heptad re-
peats was designed in accordance to the crystal structure
of HIV gp41 (PDB code 2X7R) [30], which contains the
longest helices reported to date in a lentivirus glycopro-
tein. The expressed protein was 6× His-tagged at the
N-terminus, with a tobacco etch virus (TEV) protease
recognition site, inserted before the gp45 sequence for
the removal of the His-tag. The gp45 construct, whose
sequence begins with Asp485, was expressed and puri-
fied. As expected, the overall structure of gp45 was
analogous to the reported HIV and SIV gp41 (Additional
file 1: Figure S1A-S1B) [25-27,29], with a Stable 6-helix
bundle formed by three inner NHR and three outer
CHR components (Figure 1B). However, the gp45 sur-
face is more acidic compared to gp41, consistent with its
lower calculated pI value (4.41 versus 4.92 and 5.50 in
HIV and SIV, respectively) (Additional file 1: Figure
S1C-S1E). Interestingly, the TEV cleavage recognition
sequence (ENLYFQSNA) can be clearly traced in the
electron density map, with these residues forming an
extended α-helix preceding the gp45 sequence (Figure 1B).
Crystal packing revealed that these additional residues
were involved in interactions with neighboring molecules,
which explains why the gp45 crystallization is facile, pro-
vided the 6×His-TEV sequence is retained. Despite the
high similarity of the overall structure of gp45 with HIV/
SIV gp41, the N-terminus of gp45, including residues
Figure 1 Structural properties of the EIAV gp45 protein. (A) Schematic representation of EIAV gp45. FP: fusion peptide; FPPR: fusion peptide
proximal region; NHR: N-terminal Heptad Repeats; CHR: C-terminal Heptad Repeats; MPER: membrane proximal external region; TM: transmembrane
domain; CTT: C-terminal tail. The residue numbers for demarcation of each region are shown. (B) Crystal structure of the wild-type (WT)
protein, gp45WT. The full-length trimer formed through crystallographic symmetry is shown as a ribbon model. The core of the gp45WT has
been highlighted to represent the NHR (green) and CHR (forest green) domains, and the TEV sequence is shown in palegreen. (C) Top view
of the surface charge potential of gp45 pocket. Here the negatively charged residues are colored in red and positively charged residues in
blue. (D) Superimposed structures of the EIAV gp45WT and the HIV gp41, including the FPPR (fusion peptide proximal, salmon) and MPER
(membrane proximal external, warm pink) regions (PDB code 2X7R). The EIAV gp45WT are displayed as in (B), but the TEV sequence is removed for
clarity. The HIV gp41 NHR and CHR domains are highlighted in red and raspberry colors, respectively. (E) The water clusters (represented as red spheres)
within EIAV gp45WT trimer.
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dues of gp45 (DSVQN489), pointed outwards and formed
an open pocket at the tip of the six-helix bundle (viewed
with N-terminus on top, Figure 1C). The interiors ofthe pocket were deep and considerably hydrophobic
(Figure 1C), largely attributed to the presence of the
TEV recognition sequence. For clarity, the TEV sequence
was removed from the structure for further analysis.
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carried out by superimposition of the gp45 onto a read-
ily available crystal structure of HIV gp41 (PDB code
2X7R), which contained the fusion peptide proximal
region (FPPR) and was the most complete HIV gp41
structure resolved to date. Remarkably, the FPPR at the
N-terminus of the NHR of HIV gp41 adopts an open
conformation, as in gp45, but the width of the pocket is
less pronounced than that of the latter (Figure 1D). The
HIV gp41 pocket appears partially opened in comparison
to the completely open state of gp45. The pocket con-
tains a cluster of ordered solvent molecules, coordinated
by the residues corresponding to the glutamine-rich
layer of HIV gp41 [38], i.e., Gln488, Thr491, Glu495, and
Thr498 (Figure 1E). Additionally, two water clusters are
formed through the coordination of Thr519 and Gln530
at the C-terminus of NHR (Figure 1E). Such clusters of
solvent molecules along the central axis of the six-helix
bundle are unique to gp45. In contrast, only three water
molecules are found on the axis in gp41 [29], coordi-
nated by Gln552, Gln562, and Thr569, respectively.
Crystal structure of the 505 T mutant
The crystal structure of gp45 derived from the vaccine
strain was obtained using a procedure similar to that for
the wild-type. Compared to the latter, gp45 of the vac-
cine strain has acquired a Val/Ile to Thr point mutation
at residue 505, located at the d position within the hep-
tad repeat. The crystal structure suggests that the muta-
tion has negligible effect on the overall conformation of
gp45 (Figure 2A), despite the local interaction around
residue 505, which is no longer hydrophobic, but ratherFigure 2 Structural properties of the EIAV gp45VACCINE. (A) Superimpo
in Figure 1D, and gp45VACCINE is colored in yellow for the NHR and sand for th
the element type (N, blue; O, red; C, green). (B) Thr505 in gp45VACCINE. The core
as a stick model and colored according to the element type (N, blue; O
is highlighted in red.hydrophilic. The three hydroxyl groups of Thr coordin-
ate a water molecule in the center (Figure 2B). Thr505 is
located within neighboring hydrophilic residues corre-
sponding to the Gln-rich region of gp41, despite the
presence of an EVENN sequence (E493-N497) instead of
QQQNN (HIV clade B) or QQQQQ (SIV) in EIAV gp45.
The open pocket on N-terminus of gp45 in both wide-
type and 505 T mutant reminds us a conformational
change might occur at this region during viral infection.
Interestingly, in the recently published crystal structure
of HIV gp140 Env (PDB code 4NCO), the NHR helix in
gp41 is bent in the middle (Additional file 2: Figure S2)
[39], indicating a huge conformational change for gp45/
gp41 might occur during viral infection.
Stability of the 6-helix bundle within EIAV gp45
We found that the d positions within the heptad repeats
were conserved due to their direct contribution to the
stability of the helix bundle. By sequence alignment of
the NHR regions of EIAV and HIV, we obtained distinct
differences in the residue polarity at the d positions in
EIAV and HIV, predominantly due to the switch be-
tween the hydrophobic Ile/Leu/Val and hydrophilic Thr
(Figure 3A) residues. In the EIAV vaccine strain, the V/
I505T mutation at the position 505 changes the polarity
of the residue side chains. In order to determine the
influence of this mutation on the d position, we used
circular dichroism to measure protein stability under
increased environmental temperatures. Compared to
the WT gp45, the V/I505T mutant has similar dynamics
at room temperature (Figure 3B). However, with in-
creasing temperatures, the V/I505T mutant unfoldssed structures of EIAV gp45WT and gp45VACCINE. gp45WT are shown as
e CHR. Thr505 is represented as a stick model and colored according to
of the gp45VACCINE protein is colored as in (A). Thr505 is represented
, red; C, green), and the water molecule coordinated by the Thr505
Figure 3 (See legend on next page.)
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Figure 3 Circular dichroism (CD) stability analyses of EIAV gp45 and its mutant proteins. (A) The sequence alignment of the NHR region
for both EIAV gp45 and HIV gp41 is shown. The mutants LN40 and FDDV4 refer to the sequences of the EIAV WT and vaccine strains, respectively. Two
HIV sequences, one typical clade B (HXB2) and the other from CRF07 circulating in China, are aligned against EIAV. The a and d positions are
highlighted in orange and green shadows, respectively. (B) Secondary structures of the EIAV gp45 protein and its mutants as characterized by
CD, at room temperature. The α-helices of gp45 are well-retained across all mutants. (C) Temperature sensitivity measurements. Thermostability of
gp45 and its mutants was monitored by CD at 222 nm, along a temperature gradient. (D) Secondary structures of the EIAV gp45 from the
vaccine strain, FDDV4, and its mutants characterized by CD, at room temperature. (E) Temperature sensitivity measurements of EIAV gp45
from the vaccine strain FDDV4 and its mutants. Thermostability was monitored as described above. Results are an average of three
independent experiments.
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(Tm) by approximately 20°C, indicating that the stabil-
ity of gp45 from the vaccine strain is markedly affected
(Figure 3C). Similar mutations were tested at other
d positions within the construct. We observed that a
hydrophobic to hydrophilic mutation at Leu512 to Thr
also decreased the stability of the helix bundle, albeit
with less significance (Figure 3C). In contrast, the
hydrophilic to hydrophobic mutations at residues 491,
498 and 519 increased the Tm due to the introduction
of a hydrophobic force (Figure 3C). Within the heptad
repeat, the a/d position point to the center and are crit-
ical for maintaining stability of the helix bundle by
attaching the three NHRs together. The mutation ef-
fects at a position are consistent with this observation
(Additional file 3: Figure S3A-S3B). For example, E495Q
mutation increases the Tm significantly, possibly a result
of removal of charge repulsion. Whereas conserved muta-
tions, such as L502I, I509L, and V516I have minor effects
on Tm. Due to the symmetrical packing of the three
NHRs, a mutation in one molecule at the a/d position will
introduce three corresponding mutations clustering at
the same site within the helix bundle, thus significantly
affecting the overall stability.
In the production of the vaccine EIAV, quasi-species
harboring multiple mutations were generated during
viral replication and evolution [40]. Thr505 residue exhib-
ited increased association to the vaccine strain, although
other mutations were also present in the different vaccine
strain sequences studied (Additional file 3: Figure S3C). A
dominant vaccine strain isolate, FDDV4, was used to
make the reversion mutation to test the influence of
Thr505. FDDV4 has residues S501M502 in place of
G501L502 in the WT virus (Figure 3A and C). Hence, the
T505I FDDV4 gp45 mutant was generated and measured
by circular dichroism for its influence on protein stability.
Comparable results were attained, similar to those of
previous mutants (Figure 3D-E), indicating that the
V/I505T mutation was crucial for gp45 stability, whereas
mutations including S501M502 were negligible.
EIAV replication of wild-type and vaccine strains
Since helix bundle formation provides the energy to
drive membrane fusion at the late stage of the viral entry[41], the stability of gp45 is considered critical for mem-
brane fusion efficiency and viral infection. This is con-
firmed through circular dichroism, where a decrease in
stability is usually accompanied by a reduction in viral
infection. Our previous work shows that the in vitro
replication ability in several cell lines of the vaccine
strain is comparable to that of the WT [40]. However,
our previous work is based on quasi-species composed
of multiple evolutionarily-related viral sequences. To
investigate the effect of mutations at the d position,
specifically at residue 505 within the heptad repeats, we
used infectious clones for EIAV [42] and introduced the
corresponding mutations to determine their influence
on viral replication ability in ED (Equine dermis) cells.
Using this method, we were able to exclude the influ-
ence of sequence divergence in other regions outside
the NHR. Although, the Thr mutation at residue 505
reduced the stability of gp45, replication ability was
maintained to the level of the WT (Figure 4A). The ma-
jority of the remaining mutations at d also displayed
tolerance and yielded viruses with replication compar-
able to WT, although a significant decrease was seen in
the mutant T491I (Figure 4A). This observation indi-
cated that, in spite of high conservation at the d pos-
ition, certain mutations were tolerable for the viability
of EIAV. This conclusion is also supported by the mu-
tations in the a position (Additional file 4: Figure S4).
As measured by circular dichroism, we observed that
the Tm of gp45 harboring a V505T mutation dropped to
38°C (close to the normal equine body temperature).
However, the early stage of EIAV infection, during which
the balance between the virus and host immune system
is adjusted, is characterized by febrile episodes [12]. To
determine whether fluctuations in body temperature
play a role in virus-host interaction, we measured the
viral infection ability of these mutants at varying temper-
atures. When the viral infection assay was performed at
a higher temperature of 41°C, we observed an apparent
reduction in the infection efficiency of almost all viral
mutants (Figure 4B). For the virus bearing the Thr505
mutation, this reduction was significant compared to
the WT (Figure 4C), indicating increased sensitivity to
temperature differences. An additional mutant with
reduced helix bundle stability, L512T, also displayed
Figure 4 EIAV replication kinetics and temperature sensitivity assays. (A) Replication analysis of wild-type (WT) EIAV and EIAV with mutations
at position d. The procedure employs ED cells which are infected by the virus in sets of three. EIAV replication kinetics is assayed using qPCR, by
measuring the virions in the supernatant. (B) Temperature sensitivity measurements; at 41°C, each virus experiences a infection decrease
compared to a temperature of 37°C. The same behavior is observed for WT but to a different degree. (C) The infection ratios from 37 to
41°C. The V505T mutation exhibits significant sensitivity with a considerable drop in infection as the temperature is increased. The L512T
mutant is also affected in a similar manner, while the other mutants tested show minimal differences. Results are an average of three
independent experiments.
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although the transitions were less prominent compared
to Thr505. Furthermore, the mutants harboring hydro-
philic to hydrophobic mutations T491I, T498L, and
T519L were less sensitive to temperature in comparison
with the WT (Figure 4C), possibly a result of increased
stability of the helix bundle. From these mutations, a
positive correlation between helix bundle stability andinsensitivity to rising temperatures for virus infection is
proposed, with the V505T mutant exhibiting the most
distinctive change associated with temperature dependence.
Discussion
EIAV gp45 and HIV gp41 are members of type I mem-
brane fusion proteins, which are conserved in most
RNA viruses [43]. In these proteins, the core region of
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NHR and CHR, preceded by the fusion peptide and
followed by the transmembrane region [44]. The hydro-
phobic fusion peptide is buried within the envelope tri-
mer prior to fusion and is exposed during the process,
leading to the transformation of NHR and CHR. This
highly conserved fusion machinery provides an excep-
tional opportunity to study the common mechanisms
underlying viral membrane fusion. For lentiviruses, use-
ful analogies to HIV gp41 can be drawn from studies on
gp45 of EIAV, notably in viral adaption. In the present
study, for the first time, high-resolution crystal struc-
tures of the EIAV gp45 protein have been solved. We
have carried out extensive studies on the gp45 protein
derived from both the WT and vaccine strain. Addition-
ally, a critical mutation, V/I505T, located at the highly
conserved d position within the heptad repeat, has
prompted investigations into the association of this mu-
tation within the viral attenuation mechanism.
The membrane fusion activity of gp41 is generally pro-
portional to its post-fusion stability [38]. Mutations that
reduce stability commonly lead to a reduction of fusion
ability and viral replication. In the case of gp45, a V/
I505T mutation results in a significant decrease in pro-
tein stability without an accompanying decrease in viral
replication. The crystal structure shows that this residue
is located in the center of the post-fusion six-helix bun-
dle, adjacent to the glutamine-rich layer. The glutamine-
rich layer, characterized by a hydrophilic environment
and several hydrogen bonds, is critical to the conform-
ational transition of envelope proteins (during the infec-
tion process) [45,46]. The location of this residue is
likely to be pivotal to the success of the EIAV vaccine, as
no other site within gp45 has been previously associated
with this specific vaccine strain. The lower stability of
gp45 induced by V/I505T mutation may potentially slow
down the formation of post-fusion conformation and
stabilize the pre-fusion counterpart, and consequently
provide a prolonged period for the antibodies to
recognize exposed epitopes. Recently, stabilizing the pre-
fusion conformation of the RSV F protein has proven to
be an effective strategy to induce improved antibody re-
sponses in animal models [47].
The decreased stability of gp45 by V/I505T mutation
might also favor the viral replication in specific cell lines,
such as donkey dermal cells, a hypothesis which requires
further elucidation. Our previous study identified a trun-
cating mutant of gp45 in specific vaccine strains, which
resulted in the lack of the C-terminal cytosolic region.
This mutant has lower replication in monocyte-derived
macrophage (MDM) but higher replication in fetal don-
key dermal cell (FDD), indicating an adaptation depend-
ing on the host cell context [48]. The vaccine virus
(FDDV) was adapted in 37°C by serial passing in vitro.In the absence of pressure from the host immune sys-
tem, the V/I505T mutation in gp45 may offer an advan-
tage for the virus in adaptation in specific cells (such as
FDD) by increasing the stability of Env pre-fusion con-
formation, a tendency that cannot be acquired easily in
an in vivo environment.
Our structures of EIAV gp45 also revealed differences
between EIAV gp45 and HIV gp41. EIAV gp45 had a
more loosely packed structure compared with HIV gp41,
reflected by a higher number of coordinated water mole-
cules at the center of the gp45 trimer and observed
lower melting temperatures of the six-helix bundle. The
EIAV is known to utilize the ELR1 as its sole receptor
[49], in contrast to the sequential receptor/co-receptor
usage of CD4 and CCR5/CXCR4 by HIV in viral entry
[50,51]. Therefore, the one-step transition within EIAV
suggests a simple conformational change in the EIAV
envelope protein.
Additionally, the melting temperature (Tm) of gp45 is
also likely to play a role in EIAV vaccine development.
We found that the Tm of WT gp45 was 58°C, much
lower than that of the HIV gp41 (~80°C) [29]. The gp45
of the vaccine strain, harboring the Thr505 mutation,
had a Tm of only 38°C, well within the range of normal
equine body temperature. This gp45 is expected to be
significantly sensitive to alterations in body temperature.
The EIAV vaccine strain was established by serial pass-
ing in donkey cell lines in vitro at 37°C, encouraging
viral adaptation to this temperature but making it
considerably more sensitive to temperature fluctuations
during febrile episodes. This alteration may allow the
host to control viral load easily, while simultaneously
maintaining a continuous low level of viral replication
asymptomatically and as a result driving the mutual
co-evolution of the virus and its host.
In EIAV vaccine, the attenuated vaccine virus provides
a high level of immunity, presumably due to the con-
tinuous antigen presentation and consistent optimization
of the host immune system. Recent EIAV vaccine studies
have indicated that the attenuated virus must achieve a
critical level of replication to sufficiently drive the mat-
uration of the host immune [52]. Craigo, JK et al. dem-
onstrated that in every recurring disease cycle, a new
quasi-species can appear with each fever, and the domin-
ating isolate changes each time [53]. Therefore, it is
imperative for the EIAV vaccine strain to evolve consist-
ently in vivo to achieve the effective protection required
by the host. Importantly, the level of immunity observed
with the vaccine correlates with that of the divergence
evolved from the original viral Env [35]. Hence, the stud-
ies on EIAV, including what has been reported here, pro-
vide in-depth insights for the elucidation of the vaccine
mechanism, and may be helpful for other viral vaccine
developments.
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In summary, we have carried out structural and bio-
chemical studies of the EIAV gp45 from both wide-type
and vaccine strain. A hydrophobic to hydrophilic inter-
action change in the EIAV vaccine strain was found to
modulate the stability and thermal-sensitivity of the
overall gp45 structure. Our studies suggested that the
unique features of gp45, such as loose packing and low
Tm, contribute to the success of FDDV in EIAV vaccine
development. Our studies provide useful information on
the underlying mechanism of viral adaptation during
in vitro attenuation, and direct a strategy for further de-
velopment of an effective lentiviral vaccine. Recently, the
full-length gp140 structures consisting of all the variable
regions have been reported, using both crystallographic
and cryo-electron microscopy techniques [39,54]. These
distinct structures reveal that the gp41 trimer for NHR
region is pre-formed within native viral envelope, which
implies that varying the heptad repeat residues at the
d positions can have a direct impact on the stability of
viral spikes, offering new implications for the design of
envelope protein immunogens.
Methods
Plasmids and molecular cloning
For crystallography structure analysis, the EIAV gp45
was constructed by overlapping the NHR and CHR re-
gions with a GGSGG linker. Both the NHR and CHR
were amplified by polymerase chain reaction (PCR)
using the gene encoding full-length template of EIAV
gp140 (gp90 + gp45) and further cloned by employing
the ligation-independent cloning (LIC) technique. The
pET30-TEV/LIC was digested with SspI and extracted
using a gel extraction kit (Axygen). Subsequently, the
cleaved plasmids and purified PCR products were digested
with a T4 DNA polymerase (Promega) in the presence of
dGTP or dCTP, respectively. The annealed mixture con-
taining pET30-TEV/LIC-gp45 was transformed into E.coli
DH5α competent cells for plasmid propagation. Using this
method, a 6× His-tag and a TEV cleavage site derived from
the LIC vector were fused upstream of gp45. The Quik-
Change site-directed mutagenesis kit (Stratagene) was used
to generate point mutations. All procedures were per-
formed in accordance with the manufacturer’s instructions.
Protein expression and purification
6× His-tagged gp45 was expressed in E.coli Rosetta™
(DE3) and cultured in Luria-Bertani (LB) medium, sup-
plemented with kanamycin (50 μg/mL). The cells were
grown at 37°C until an OD600 of 0.8 was reached. Re-
combinant protein expression was induced by the
addition of 200 μM isopropyl β-D-1-thiogalactopyrano-
side (IPTG) and allowed to proceed for 12 h at 20°C.
The cells were harvested by centrifugation (6000 × g, for20 min, at 20°C) and re-suspended in a buffer consisting
of 25 mM Tris, 500 mM NaCl, 20 mM imidazole, at
pH 8.0. Subsequently, cells were lysed by sonication and
the crude extract was clarified by centrifugation at
38,000 × g, for 40 min at 4°C.
The supernatant was applied onto a pre-equilibrated
Ni–NTA resin, consisting of buffer A (25 mM Tris,
500 mM NaCl, at pH 8.0) and transferred into a column.
The column was washed five times with buffer A con-
taining 40 mM imidazole. Subsequently, proteins bound
to the column were eluted with the buffer containing
500 mM imidazole. The eluent was further purified
using a Q-Sepharose HiTrap HP column (GE Health-
care) with a linear concentration gradient of NaCl ran-
ging from 100 to 500 mM. Peak fractions were collected
and polished using a Superdex-200 gel filtration column
(GE Healthcare). The purified protein was concentrated
to 15 mg/mL and its purity was determined to be >95%,
as analyzed by SDS-PAGE and Coomassie blue staining
(data not shown).
Crystallization
Crystals of EIAV gp45WT (derived from the sequence of
strain LN40) were grown using the sitting-drop vapor
diffusion method at a constant temperature of 20°C; by
mixing equal volumes (1:1 μL) of both the protein
(15 mg/mL in 20 mM Tris, 500 mM NaCl, pH 8.0) and
reservoir (0.1 M Bis-Tris, 2 M NaCl, pH 5.5) solutions.
EIAV gp45VACCINE crystals (gp45WT with the V505T mu-
tation) were grown at 20°C in 0.2 M NaCl, 0.1 M sodium
acetate trihydrate, 30% v/v (+/−)-2-methyl-2,4-pentane-
diol, at pH 4.6. Following this, the gp45WT crystals were
immersed in 100% paraffin oil for several seconds and
the gp45VACCINE crystals were washed in the reservoir
solution, prior to freezing in liquid nitrogen for storage.
Data collection and structure determination
Data collection was performed at the Shanghai Synchro-
tron Radiation Facility. All datasets were collected at a
wavelength of 0.9792 Å (at 100 K), processed using the
HKL2000 package [55], and converted to amplitude
using the CCP4 suite [56]. Data collection and process-
ing results are summarized in Additional file 5: Table S1.
The structure of EIAV gp45WT was solved by molecu-
lar replacement using the HIV gp41 structure (PDB code
2X7R) as a search model. Initial models were refined
with Phenix [57] accompanied by several cycles of manual
building using COOT [58]. Simulated annealing, pos-
itional and B-factor refinements were used in multiple
rounds to improve the overall quality of the structure.
Ordered water molecules were added to the structure
in the last round of refinement. The structure of EIAV
gp45VACCINE was solved following similar procedures
by using gp45WT as the initial model. All models had low
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and no Ramachandran outliers. The refinement statistics
are summarized in Additional file 5: Table S1.
Circular dichroism spectroscopy
The protocol was adapted from a previously published
method [29,59]. Briefly, circular dichorism spectra
were acquired on a Biologic M450 spectropolarimeter
(BioLogic Science Inc., France) equipped with a thermo-
electric temperature controller. Spectra of each protein
were measured in PBS buffer, at 5°C in 1 nm increments,
from 190 to 250 nm. For thermal denaturation measure-
ments, the ellipticity was measured at 222 nm with 1°C in-
crements from 20°C to 95°C, at a rate of 90°C/h. Thermal
melting (Tm) points were calculated with a Boltzmann
sigmoidal fit using OriginLab.
EIAV and mutants production
Wild-type (WT) EIAV was generated from an infectious
molecular clone. The clone EIAV UK3 [4] was generously
provided by Dr. Montelaro (University of Pittsburgh). The
QuikChange site-directed mutagenesis kit (Stratagene)
was used to generate point mutations. Viruses were pro-
duced in ED (Equine dermis, ATCC CCL57) cells by
transfection of the infectious clone using Lipofectamine
2000 (Invitrogen). The EIAV viruses were harvested from
cultured supernatants at 72 h post-transfection. After cen-
trifugation at 1,500 × g for 10 min, the supernatants were
separated through a 0.45 μm filter and stored at −80°C.
Viral titers were determined by quantitative PCR (qPCR).
Quantified viruses were used for infection of the next
passage of ED cells.
RNA isolation and quantitative PCR (qPCR)
Viral RNA was isolated from a 140 μl supernatant using
the Qiagen Viral RNA Mini Kit and the whole-cell RNA
was isolated using Trizol reagent. In general, the mono-
layer cultures were rinsed with ice-cold PBS (50 mM
phosphate, 150 mM NaCl, at pH 7.4) and lysed upon the
addition of 100 μl Trizol in each well, when using a
96-well plate. Phase separation was performed by adding
chloroform to the wells and the RNA was precipitated
using isopropanol. Finally the RNA pellet was washed in
75% ethanol, air-dried, and re-dissolved in water.
The isolated RNA was reverse transcribed and ampli-
fied using reverse transcription PCR (RT-PCR) with a
PrimeScriptTM RT reagent kit, gDNA Eraser (TaKaRa)
and SYBR Premix Ex TaqTM (TaKaRa); SYBR standards
RSq > 0.98, 95% < Eff. <105%.
EIAV replication kinetics and temperature
dependent studies
To measure the replication kinetics of EIAV, ED cells
(5,000 cells/well) were infected by wild-type (UK3) andmutant EIAV viruses (5 × 106 copies/well). In this case,
the supernatant was harvested in 2-day intervals, up
to 12 days post-infection. Based on the isolated viral
RNA, the virus number was quantified to produce
replication curves.
To examine the temperature dependence of EIAV and
its mutants for viral entry, ED cells were incubated at
41°C for 2 h, prior to infection. Upon exposure, the cells
were incubated for a further 2 h. Total RNA was then
isolated from the infected cells and the number of EIAV
entering the ED cells was determined using qPCR.
Accession number
Atomic coordinates and structure factors have been
deposited in to the RCSB Protein Data Bank under ID
codes 3WMI and 3WMJ for gp45WT, gp45VACCINE,
respectively.
Additional files
Additional file 1: Figure S1. Supporting data for the EIAV gp45WT
structure. (A) Superimposed structures of EIAV gp45WT (from Figure 1D)
and the HIV CRF07 gp41 protein. The HIV CRF07 gp41 NHR and CHR
domains are highlighted in magenta and pink colors, respectively, with a
linker (yellow) between them. (B) Superimposed structures of EIAV
gp45WT (from Figure 1D) and the SIV gp41 protein. The SIV gp41 NHR
and CHR domains are highlighted in cyan and orange colors, respectively.
(C-E) Surface charge potentials of the EIAV gp45, HIV CRF07 gp41, and SIV
gp41. Negatively charged residues are colored in red and positively
charged residues in blue.
Additional file 2: Figure S2. Superimposition of gp45VACCINE NHR and
HIV gp41 NHR derived from crystal structure of Env trimer (PDB code
4NCO). Side-view for (A) and top-view for (B). gp45VACCINE NHR is shown
as in Figure 2A and gp41 NHR is shown in blue.
Additional file 3: Figure S3. Supporting data for the EIAV gp45 mutant
proteins. (A) Secondary structure representation of the EIAV gp45
mutants at position a, characterized by CD. (B) Thermostability results
monitored by CD (at 222 nm) for the a mutants. (C) Sequence alignment
of the EIAV gp45 ecto-domain. The LN40 represents the WT pathogenic
strain isolated in Liaoning Province, China. The DV/DLV34/DLV61 series is
classed as a pathogenic strain; the DLV121/DLV137/FDDV4/FDDV13/
FDDV23 as non-pathogenic; with DLV91 depicted as the intermediate.
The UK3 pathogenic strain is used in this study to construct the infectious
clone. The specific residue at the 505 position is shown in green shadow.
Additional file 4: Figure S4. Replication analyses of the EIAV mutants
at position a (as depicted in Figure 4A).
Additional file 5: Table S1. X-ray crystallographic data and refinement
statistics for EIAV gp45.
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